Schrage Birgit, Duan Guowen, Yang Lily P, Fraser John D, Proft Thomas
Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Clin Infect Dis. 2006 Sep 15;43(6):743-6. doi: 10.1086/507037. Epub 2006 Aug 8.
Eight different batches of intravenous immunoglobulin from 3 different manufacturers were tested for neutralizing activities against all currently known streptococcal superantigens. Statistically significant variation among different intravenous immunoglobulin preparations (P<.0001) and between individual streptococcal superantigens (P<.0001) was observed. These results might be helpful for optimizing the type and dose of intravenous immunoglobulin used in adjunctive therapy for severe invasive streptococcal disease.
对来自3个不同制造商的8个不同批次的静脉注射免疫球蛋白进行了测试,以检测其对所有目前已知的链球菌超抗原的中和活性。观察到不同静脉注射免疫球蛋白制剂之间(P<0.0001)以及各个链球菌超抗原之间(P<0.0001)存在统计学上的显著差异。这些结果可能有助于优化用于严重侵袭性链球菌疾病辅助治疗的静脉注射免疫球蛋白的类型和剂量。